Compare GPMT & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | OKYO |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 71.4M |
| IPO Year | 2017 | 2021 |
| Metric | GPMT | OKYO |
|---|---|---|
| Price | $5.30 | $1.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.50 | $8.33 |
| AVG Volume (30 Days) | ★ 166.4K | 56.3K |
| Earning Date | 11-04-2026 | 07-20-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | ★ 73.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $308.01 | N/A |
| Revenue Next Year | $8.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $1.26 |
| 52 Week High | $7.61 | $3.20 |
| Indicator | GPMT | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 47.40 |
| Support Level | $1.26 | $1.29 |
| Resistance Level | $7.61 | $1.72 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 66.73 | 51.02 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.